Corticorelin acetate has steroid-sparing effect in brain cancer

Corticorelin acetate has steroid-sparing effect in brain cancer
Corticorelin acetate administration to patients with peritumoral brain edema allows the reduction of steroid doses and is associated with reduced incidence and severity of steroid-induced myopathy and other steroid-related adverse effects, according to research published online Feb. 4 in the Journal of Clinical Oncology.

(HealthDay)—Corticorelin acetate (CrA) administration to patients with peritumoral brain edema (PBE) allows the reduction of steroid doses and is associated with reduced incidence and severity of steroid-induced myopathy and other steroid-related adverse effects, according to research published online Feb. 4 in the Journal of Clinical Oncology.

Lawrence Recht, M.D., of the Stanford University School of Medicine in Palo Alto, Calif., and colleagues conducted a 12-week, prospective, randomized, double-blind study involving 200 patients with a and PBE who had been on a stable dose of dexamethasone. The safety and efficacy of CrA was compared with placebo.

The researchers observed a clinically important but not statistically significant difference in the percentage of responders to CrA compared with placebo (57 and 46 percent, respectively). However, the maximum percent reduction in dexamethasone dose was significantly higher for CrA-treated versus placebo-treated patients (62.7 versus 51.4 percent). Overall, patients who received CrA were less likely to develop Cushing's syndrome signs and also experienced improved steroid-induced myopathy.

"This is the first randomized, placebo-controlled, double-blind study demonstrating an agent's corticosteroid-sparing effect for PBE," the authors write. "CrA administration was not only effective in lowering corticosteroid dosage over a several-week period but also was associated with decreased corticosteroid adverse effects as demonstrated by an improvement in the natural history of corticosteroid-associated myopathy, Cushingoid signs and symptoms, blood glucose, and ."

Several authors disclosed to Celtic Pharma, manufacturer of corticorelin acetate.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Obese asthma patients have reduced treatment response

date Jun 25, 2012

(HealthDay) -- Compared with lean patients, obese patients with asthma have higher neutrophil counts and a reduced response to corticosteroid treatment, according to a study published online June 12 in Allergy.

Recommended for you

Vortex device makes for better cancer treatments

date 15 hours ago

A South Australian invention, responsible for unboiling an egg, has been used to produce a four-fold increase in efficacy of carboplatin, a commonly used drug for ovarian, lung and other cancer. ...

Using healthy skin to identify cancer's origins

date May 21, 2015

Normal skin contains an unexpectedly high number of cancer-associated mutations, according to a study published in Science. The findings illuminate the first steps cells take towards becoming a cancer and de ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.